TORONTO, Oct. 31, 2024 /CNW/ - LifeSpeak Inc. ("LifeSpeak" or the "Company") (TSX: LSPK), a leading provider of mental, physical, and family wellbeing solutions for employers, health plans, and other organizations, announced today that it will release its third quarter 2024 financial results before market open on Thursday, November 7, 2024.
The Company will subsequently hold a conference call to provide a business update on Thursday, November 7, 2024, at 8:30 a.m. ET hosted by:
A question-and-answer session will follow the business update.
CONFERENCE CALL DETAILS | |
DATE: | Thursday, November 7, 2024 |
TIME: | 8:30 a.m. ET |
DIAL-IN NUMBERS: | 1.800.715.9871 or 1.646.307.1963 |
REFERENCE NUMBER: | 1042138 |
This live call is also being webcast and can be accessed by going to: https://events.q4inc.com/attendee/604155768
An archived telephone replay of the call will be available for two weeks by dialing 1.800.770.2030 or 1.609. 800.9909 and entering access code 1042138.
About LifeSpeak Inc.
Celebrating 20 years of supporting wellbeing, LifeSpeak Inc. is the leading provider of mental, physical, and family wellbeing solutions for employers, health plans, and other organizations across the globe. With a suite of digital solutions, LifeSpeak enables organizations to deliver best-in-class content and human expertise at scale, catering to individuals throughout their wellbeing journeys. The LifeSpeak Inc. portfolio of solutions spans every pillar of wellbeing, including LifeSpeak Mental Health & Resilience, Wellbeats Wellness, Torchlight Parenting & Caregiving, ALAViDA Substance Use, and LIFT session Fitness. Insights from LifeSpeak Inc.'s digital and data-driven solutions empower organizations and individuals to take impactful action to strengthen wellbeing and maximize workplace performance. To learn more, follow LifeSpeak Inc. on LinkedIn, or visit http://www.LifeSpeak.com.
| Last Trade: | C$0.37 |
| Daily Volume: | 0 |
| Market Cap: | C$21.880M |
November 07, 2024 May 08, 2024 March 21, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
